Carlos Robles, MD
Medical Oncology · Cape Girardeau, MONPI 1992755441
Payments from drug & device makers
Across 248 payments — averaging $39.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$3K
- Pentax Of America, Inc.$1K
- AstraZeneca$793
- Johnson & Johnson$598
- E.r. Squibb & Sons, L.L.C.$533
- Gilead$453
- plus $4K from 32 others
What the payments were for
- Consulting fees$1,20015%
- Food & beverage$5,94676%
- Education$6578%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 55 | $2,595 |
| Pentax Of America, Inc. | 1 | $1,200 |
| AstraZeneca | 19 | $793 |
| Johnson & Johnson | 19 | $598 |
| E.r. Squibb & Sons, L.L.C. | 10 | $533 |
| Gilead | 19 | $453 |
| EMD Serono, Inc. | 17 | $445 |
| Seagen Inc. | 11 | $380 |
| Incyte Corporation | 5 | $373 |
| Eisai Inc. | 7 | $248 |
| Novartis | 7 | $194 |
| Heron Therapeutics, Inc. | 5 | $180 |
| Myriad Genetic Laboratories, Inc. | 6 | $175 |
| Bristol Myers Squibb | 14 | $173 |
| Pharmacosmos Therapeutics Inc. | 2 | $167 |
| Genentech USA, Inc. | 2 | $155 |
| Daiichi Sankyo Inc. | 4 | $130 |
| Regeneron Healthcare Solutions, Inc. | 6 | $125 |
| Stemline Therapeutics Inc. | 4 | $118 |
| Amgen | 5 | $104 |
| Dendreon Pharmaceuticals LLC | 2 | $100 |
| AbbVie | 4 | $72 |
| Pfizer | 3 | $71 |
| GSK | 2 | $51 |
| Sanofi | 3 | $50 |
| Tempus AI, Inc | 2 | $46 |
| Jazz Pharmaceuticals Inc. | 2 | $42 |
| Exelixis Inc. | 2 | $32 |
| Medtronic | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Beigene USA, Inc. | 1 | $27 |
| Beone Medicines USA, Inc. | 1 | $24 |
| Tersera Therapeutics LLC | 1 | $24 |
| Adaptive Biotechnologies Corporation | 1 | $19 |
| Verastem, Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $13 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,805 in reported general payments places this provider in the 35th percentile of 144 medical oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 41 | $743,850 |
| ImbruvicaIbrutinib | 21 | $320,388 |
| KisqaliRibociclib Succinate | 18 | $291,358 |
| SprycelDasatinib | 14 | $200,871 |
| XtandiEnzalutamide | 11 | $160,807 |
| Imatinib Mesylate | 21 | $58,246 |
| EliquisApixaban | 41 | $22,446 |
| TrexallMethotrexate Sodium | 17 | $5,004 |
| Ondansetron Hcl | 102 | $4,027 |
| Hydroxyurea | 53 | $2,383 |
| Exemestane | 20 | $2,126 |
| Anastrozole | 154 | $1,843 |
| Fentanyl | 17 | $1,486 |
| Dexamethasone | 107 | $1,481 |
| Prochlorperazine Maleate | 73 | $884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $173 | $743,85041 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $12 | $320,38821 claims |
| NovartisKisqali | $194 | $291,35818 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $533 | $200,87114 claims |
| PfizerEliquis | $71 | $22,44641 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 144 medical oncology providers in Missouri.
Other medical oncology in Cape Girardeau
- Michael NaughtonCape Girardeau$479K
- Nina Wagner JohnstonSaint Louis$22M
- Cynthia MaSaint Louis$22M
- Nancy BartlettSaint Louis$19.9M
- Douglas AdkinsSaint Louis$19.2M
- Ramaswamy GovindanSaint Louis$16.4M
- Timothy PluardKansas City$14.7M
- Kelly BoltonSaint Louis$14.5M
- Ravi VijSaint Louis$14.4M
- Daniel MorgenszternSaint Louis$12.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.